Home Mass spectrometry measurement of plasma hepcidin for the prediction of iron overload
Article
Licensed
Unlicensed Requires Authentication

Mass spectrometry measurement of plasma hepcidin for the prediction of iron overload

  • Annarosa Floreani EMAIL logo , Filippo Navaglia , Erik Rosa Rizzotto , Daniela Basso , Maria Chiaramonte , Andrea Padoan , Ioannis Petridis , Nora Cazzagon , Roberto Testa , Maurizio Marra , Mario Plebani and Arsita Two Research Group
Published/Copyright: December 14, 2010

Abstract

Background: Hepcidin has emerged as the primary regulator of iron homeostasis. Previous studies on assessing urinary hepcidin are limited. We developed a method for quantifying hepcidin-25 (Hep-25) in plasma using surface-enhanced laser-desorption-ionization time-of-flight mass spectrometry (SELDI-TOF/MS) and a 25-AA peptide as reference standard. The aims of the study were 1) to assess the performance of this method in different conditions of iron metabolism disorders; 2) to assess the diagnostic validity of non-invasive serum biomarkers in the identification of iron overload.

Methods: Validation of the method was performed in 10 patients with type I hemochromatosis (HE) and in 177 subjects previously enrolled in a general population epidemiological study. Among the latter group, 17 had non-alcoholic fatty liver disease, 10 had chronic hepatitis C, and 150 subjects had normal ultrasound, normal liver function tests (LFTs), an alcohol intake <20 g ethanol/day and were negative for the C282Y mutation. The following biomarkers were assayed in each case: plasma Hep-25, C282Y and H63D mutations of the HFE gene; serum iron, ferritin (SF), transferrin saturation, transaminases, γ-glutamyltransferase (GGT), glucose, insulin, total cholesterol, high-density lipoprotein (HDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol and triglycerides.

Results: Plasma Hep-25 concentrations were higher in HCV+ patients (26.3±7.2 nmol/L) than in controls, and correlated positively with SF (p<0.001). H63D heterozygous subjects revealed a pattern of iron overload that was significantly higher than H63D wild type subjects. Analyzing the data with the Biomarker Pattern 5.0.2. software to identify the most significant biomarkers for discriminating between HE cases and controls allowed us to produce an algorithm with four terminal nodes, which included glucose >4.8 mmol/L and Hep-25/SF ratio ≤6.6 as the main splitters. These variables enabled the correct diagnosis of HE with 100% sensitivity, 93% specificity and an area under the receiver operating characteristic (ROC) curve of 0.993.

Conclusions: Our plasma Hep-25 mass spectrometry method yields measurements that reflect pathological and genetic influences; simple non-invasive biomarkers (Hep-25/SF ratio and glucose) can predict the presence of HE.


Corresponding author: Prof. Annarosa Floreani, Department of Surgical and Gastroenterological Sciences, University of Padova, Via Giustiniani 2, 35128 Padova, Italy Phone: +39 049 821 2894

Received: 2010-4-24
Accepted: 2010-7-31
Published Online: 2010-12-14
Published in Print: 2011-02-01

©2011 by Walter de Gruyter Berlin New York

Articles in the same Issue

  1. Editorial
  2. Hepcidin: the main regulator of iron homeostasis
  3. Reviews
  4. Global trends in critical values practices and their harmonization
  5. Ischemia modified albumin changes – review and clinical implications
  6. Genetics and Molecular Diagnostics
  7. Decreased serum brain-derived neurotrophic factor (BDNF) is associated with post-stroke depression but not with BDNF gene Val66Met polymorphism
  8. A novel liquidchip platform for simultaneous detection of 70 alleles of DNA somatic mutations on EGFR, KRAS, BRAF and PIK3CA from formalin-fixed and paraffin-embedded slides containing tumor tissue
  9. General Clinical Chemistry and Laboratory Medicine
  10. Mass spectrometry measurement of plasma hepcidin for the prediction of iron overload
  11. Serum hepcidin-25 in comparison to biochemical markers and hematological indices for the differentiation of iron-restricted erythropoiesis
  12. The quality of the extra-analytical phase of laboratory practice in some developing European countries and Mexico – a multicentric study
  13. Impact of cryopreservation on serum concentration of matrix metalloproteinases (MMP)-7, TIMP-1, vascular growth factors (VEGF) and VEGF-R2 in Biobank samples
  14. Determinants of circulating asymmetric and symmetric dimethylarginines in patients evaluated for acute dyspnea
  15. Urinary stone composition in pediatric patients: a retrospective study of 205 cases
  16. Electrolyte-balanced heparin in blood gas syringes can introduce a significant bias in the measurement of positively charged electrolytes
  17. Full-scan mass spectral evidence for 3-epi-25-hydroxyvitamin D3 in serum of infants and adults
  18. Association of nucleated red blood cells in blood and arterial oxygen partial tension
  19. Validation and Outcome Studies
  20. Cystatin C is a reliable marker for estimation of glomerular filtration rate in renal transplantation: validation of a new turbidimetric assay using monospecific sheep antibodies
  21. Analytical validation of the Liaison Calcitonin_II-Gen (DiaSorin)
  22. A new tool in the field of in-vitro diagnosis of allergy: preliminary results in the comparison of ImmunoCAP© 250 with the ImmunoCAP© ISAC
  23. Rapid microwave digestion and microplate reading format method for urinary iodine determination
  24. Reference Values and Biological Variations
  25. Serum creatinine concentrations in male and female elite swimmers. Correlation with body mass index and evaluation of estimated glomerular filtration rate
  26. Biological variation of free β chorionic gonadotropin and pregnancy-associated plasma protein A in first trimester pregnancies
  27. Non-infectious conditions and gestational age influence C-reactive protein values in newborns during the first 3 days of life
  28. Cancer Diagnostics
  29. Interpretation of increments in serial tumour biomarker concentrations depends on the distance of the baseline concentration from the cut-off
  30. Performance of nuclear matrix protein 22 urine marker and voided urine cytology in the detection of urinary bladder tumors
  31. High-performance metabolic marker assessment in breast cancer tissue by mass spectrometry
  32. BRAF analysis by fine needle aspiration biopsy of thyroid nodules improves preoperative identification of papillary thyroid carcinoma and represents a prognostic factor. A mono-institutional experience
  33. Letters to the Editor
  34. Stat laboratory timeliness management according to clinician needs
  35. Stability of serum samples and hemolysis interference on the high sensitivity troponin T assay
  36. Falsely diminished results for insulin concentrations measured with the IMMULITE® 2000
  37. Neutrophil gelatinase-associated lipocalin (NGAL) determined in urine with the Abbott Architect or in plasma with the Biosite Triage? The laboratory's point of view
Downloaded on 10.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2011.055/html
Scroll to top button